SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001346302-20-000073
Filing Date
2020-11-16
Accepted
2020-11-16 07:26:10
Documents
15
Period of Report
2020-11-16
Items
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K xers-20201116.htm   iXBRL 8-K 40016
2 EX-10.1 exh101formofexchangeag.htm EX-10.1 88171
  Complete submission text file 0001346302-20-000073.txt   320688

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xers-20201116.xsd EX-101.SCH 2420
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT xers-20201116_cal.xml EX-101.CAL 708
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT xers-20201116_def.xml EX-101.DEF 15623
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xers-20201116_lab.xml EX-101.LAB 30040
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xers-20201116_pre.xml EX-101.PRE 16292
8 EXTRACTED XBRL INSTANCE DOCUMENT xers-20201116_htm.xml XML 11507
Mailing Address 180 NORTH LASALLE STREET SUITE 1600 CHICAGO IL 60601
Business Address 180 NORTH LASALLE STREET SUITE 1600 CHICAGO IL 60601 844-445-5704
XERIS PHARMACEUTICALS INC (Filer) CIK: 0001346302 (see all company filings)

IRS No.: 203352427 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38536 | Film No.: 201313666
SIC: 2834 Pharmaceutical Preparations